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Abstract
Pituitary tumors are common intracranial neoplasms, yet few germline abnormalities have been implicated in their
pathogenesis. Here we show that a single nucleotide germline polymorphism (SNP) substituting an arginine (R) for glycine
(G) in the FGFR4 transmembrane domain can alter pituitary cell growth and hormone production. Compared with FGFR4-
G388 mammosomatotroph cells that support prolactin (PRL) production, FGFR4-R388 cells express predominantly growth
hormone (GH). Growth promoting effects of FGFR4-R388 as evidenced by enhanced colony formation was ascribed to Src
activation and mitochondrial serine phosphorylation of STAT3 (pS-STAT3). In contrast, diminished pY-STAT3 mediated by
FGFR4-R388 relieved GH inhibition leading to hormone excess. Using a knock-in mouse model, we demonstrate the ability
of FGFR4-R385 to promote GH pituitary tumorigenesis. In patients with acromegaly, pituitary tumor size correlated with
hormone excess in the presence of the FGFR4-R388 but not the FGFR4-G388 allele. Our findings establish a new role for the
FGFR4-G388R polymorphism in pituitary oncogenesis, providing a rationale for targeting Src and STAT3 in the personalized
treatment of associated disorders.
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Introduction
Pituitary tumors occur in almost 20% of the population [1] and
represent nearly 10% of surgically resected intracranial tumors [2–
3]. They can cause significant health problems due to abnormal
hormone productionand invasion intosurrounding brain structures
[2–3]. However, the mechanisms underlying the development of
sporadic pituitary tumors that rarely involve mutations of classical
oncogenes or tumor suppressor genes remain to be clarified [2–3].
Indeed, the only consistent molecular event reported thus far is
activating mutations of the G-protein coupled Gsa that occurs in a
subset of somatotroph adenomas [4–5]. Germline genetic abnor-
malities associated with pituitary tumor pathogenesis include
inactivating mutations ofmeninin patients with Multiple Endocrine
Neoplasia type 1 [6–7], loss of function mutations of the aryl
hydrocarbon receptor-interacting protein (AIP) tumor suppressor
gene in patients with familial isolated pituitary adenomas [8], and
activating mutations the Protein kinase A type I regulatory subunit
PRKA [9] in patients with Carney complex, however these
alterations have not been shown to mediate pituitary neoplastic
growth in the more common sporadic neoplasms.
Evidence suggests that epigenetically controlled growth signals
implicated in pituitary development may be relevant to the
tumorigenic processes in this gland [10–11]. Of note members of
the fibroblast growth factor (FGF) and FGF receptor families have
been proposed as candidate effectors, given their recognized
importance in pituitary organogenesis [12–13]. FGF signaling is
critical in pituitary development. Deletion of FGF10 or its
receptor, the FGFR2 IIIb isoform, leads to failure of pituitary
development [13]. Mid-gestational expression of a soluble
dominant-negative FGFR results in severe pituitary dysgenesis
[14]. FGF ligands are over-expressed in pituitary tumors. FGF-2,
originally described in bovine pituitary folliculostellate cells,
regulates multiple pituitary hormones and is over-expressed by
human pituitary adenomas tumors [15].
We identified altered FGFR4 expression in pituitary tumors
[16] due to expression of an N-terminally deleted isoform,
pituitary tumor-derived FGFR4 (ptd-FGFR4) [17] generated by
alternative transcription initiation from a cryptic promoter [18–
19]. Prototypic FGFR4 (FGFR4-G388) is a 110 kD membrane-
anchored protein expressed in several endocrine cells including the
normal pituitary. In contrast, ptd-FGFR4 is a cytoplasmic protein
expressed in pituitary tumors. The invasive tumorigenic potential
of ptd-FGFR4, but not full length FGFR4, was demonstrated by
targeted pituitary expression in transgenic mice [17]. The basis for
the contrasting functions between these FGFR4 isoforms relates to
their differential ability to associate with neural cell adhesion
molecule (NCAM) and engage N-cadherin [20].
PLoS Genetics | www.plosgenetics.org 1 December 2011 | Volume 7 | Issue 12 | e1002400These studies were all carried out with the prototypic receptor
prior to the identification of a single nucleotide polymorphism
(SNP) that alters the coding region of the transmembrane domain.
This germ-line polymorphism substitutes a glycine with an
arginine at codon 388 of FGFR4, resulting in a charged amino
acid in the highly conserved and normally hydrophobic trans-
membrane region of the receptor [21]. This FGFR4-R388 allele
has been linked with advanced [21] and treatment-resistant breast
cancer [22], prostate cancer [23], sarcomas [24], and head and
neck carcinomas [25]. The mechanisms underlying FGFR4-R388
actions remain unclear. In this report we identify distinct signaling
and hormone regulatory properties that distinguish FGFR4-R388
from the prototypic FGFR4-G388 form. The data unmask
important patho-physiologic consequences of this common SNP
with therapeutic implications for related diseases.
Results
The FGFR4-R388 polymorphic allele deregulates pituitary
hormone production and cell growth
To determine if the FGFR4 polymorphic isoforms possess
distinct functional properties in hormone-producing pituitary cells,
we compared the effects of FGFR4-G388 and FGFR4-R388 on
pituitary hormone production in rat GH4 mammosomatotroph
cells that co-express prolactin (PRL) and growth hormone (GH)
and in PRL235 cells that express PRL only. These GH4 and
PRL235 cells express endogenous FGFR4 (Figure S1) and are
homozygous for FGFR4-G385, the rodent equivalent of the
human 388 site. Expression of human FGFR4-G388 or FGFR4-
R388 to comparable levels shows that FGFR4-G388 enhances
PRL and suppresses GH expression whereas FGFR4-R388
increases GH production with a reciprocal effect on PRL
(Figure 1a, 1b).
To determine the effects of these FGFR4 isoforms on cell
growth, stably transfected cells were plated in soft agar and
examined for colony formation. GH4 cells expressing FGFR4-
R388 were more efficient at forming colonies in soft agar
compared with their FGFR4-G388 counterparts (Figure 1c; left).
Enhanced colony formation resulting from FGFR4-R388 com-
pared to FGFR4-G388 was also noted in PRL235 pituitary cells
(Figure 1c; right).
The FGFR4-R388 polymorphic allele promotes
Src-dependent responses in pituitary cells
The FGFR4-R388 substitution does not alter receptor kinase
activity [21] and (data not shown). Thus, to examine signaling
differences induced by the two FGFR4 isoforms in pituitary cells,
we compared the ability of FGF to promote phosphorylation of the
immediate FGFR substrate FRS2a. In contrast to FGFR4-G388
which showed ligand-dependent stimulation of this docking
protein, FGFR4-R388 cells displayed enhanced FRS2a phos-
phorylation (Figure 2a). Src phosphorylation at Y416 was also
appreciably higher in cells expressing FGFR4-R388 compared to
those expressing FGFR4-G388 while Src phosphorylation at Y527
remained unchanged.
To examine the functional significance of this finding, we
compared the ability of the Src inhibitor, dasatinib, to impede
pituitary tumor cell growth and hormone production. Dasatinib
effectively diminished Src phosphorylation (Figure 2b) and
significantly inhibited colony formation in soft agar of cells
expressing FGFR4-R388 (Figure 2c). By comparison, the less
efficient colony forming FGFR4-G388 cells were relatively
insensitive to the Src inhibitor (Figure 2c).
In contrast to the impact on cell growth, pharmacologic Src
inhibition did not alter GH or PRL hormone expression
(Figure 2b). Additionally, siRNA-mediated Src down-regulation
did not significantly affect GH (Figure 2d) or PRL levels (data not
shown). These findings suggested that while Src may play a role in
driving FGFR4-R388-mediated cell growth, Src signaling may not
be intimately coupled with pituitary hormone regulation in these
cells.
FGFR4-R388 promotes STAT3 serine, but not tyrosyl,
phosphorylation in pituitary cells
STAT activation is implicated in mediating the effects of
FGFR3 mutations associated with thanatophoric dysplasia [26].
We, therefore, examined the ability of the two FGFR4 isoforms to
activate STAT signaling. Figure 2a depicts the differential impact
of the FGFR4 isoforms on their ability to phosphorylate STAT3.
While FGFR4-G388 supported ligand-induced tyrosyl phosphor-
ylation of STAT3, this effect was not shared with FGFR4-R388,
which instead resulted in sustained STAT3 serine phosphorylation
at S727 (Figure 2a). STAT1 and STAT5 modifications were not
affected by either FGFR4 isoform in GH4 or PRL235 cells (data
not shown).
In contrast to the nuclear residence of pY-STAT3, pS-STAT3
translocates to the mitochondria where it has been implicated in
cellular metabolism [27]. Thus, we performed immunofluores-
cence to localize pS-STAT3. Figure 3a identifies the mitochon-
drial residence of pS-STAT3 in FGFR4-R388; FGFR4-G388 cells
are almost negative (upper panels). As controls, we expressed a
constitutively active serine form of STAT3 (STAT3-S727D) in
GH4 cells, and this also co-localized to the mitochondria
(Figure 3a). In contrast, an inactive serine form of STAT3
(STAT3-S727A) failed to show a mitochondrial signal (Figure 3a).
Subcellular fractionation followed by western blotting supported
these findings with prominent mitochondrial expression of STAT3
and pS-STAT3 in FGFR4-R388 and in STAT3-S727D control
but not in FGFR4-G388 cells in both GH4 and PRL235 cells
(Figure 3b).
To examine the impact of pS-STAT3 on mitochondrial
function, we measured Cytochrome C oxidase activity in pituitary
cells expressing the different FGFR4 isoforms (Figure 3c). FGFR4-
R388 cells which displayed higher pS-STAT3 levels also
demonstrated higher Cytochrome C oxidase activity than
FGFR4-G388 cells. In addition, lactate dehydrogenase (LDH)
levels in FGFR4-R388 cell lysates were higher (2612 IU/ml) than
those of the FGFR4-G388 (1197 IU/ml; n=3).
To examine the functional impact of distinct STAT3 modifi-
cations on pituitary cells we compared growth in soft agar of cells
expressing various STAT3 expression vectors (Figure S2). Of the
STAT3 modifications, the active serine (STAT3-S727D) form
displayed the greatest positive impact on colony formation (Figure
S2).
Author Summary
Several human cancers have been associated with
increased growth hormone levels. Here we show that a
frequent single nucleotide polymorphism (SNP) associated
with increased cancer risk and progression also deregu-
lates pituitary function. Through recruitment of a distinct
STAT3 signaling cascade, this polymorphic receptor variant
drives pituitary growth hormone cell survival and hor-
monal output. These findings provide an example of a
potentially common genetic program shared between
cancer and a hormone that promotes its progression.
FGFR4 Polymorphism in Pituitary Tumorigenesis
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were inter-dependent, we examined the impact of pharmacologic
Src inhibition. To this end, dasatinib-mediated inhibition of Src
phosphorylation also reduced pS-STAT3 in FGFR4-R388 GH4
cells (Figure 2b). Moreover, siRNA-mediated Src down-regulation
also resulted in diminished pS-STAT3 levels in these cells
(Figure 2d). Additionally, treatment with the protein kinase C
inhibitor G06983 reduced pS-STAT3 whereas the protein kinase
A inhibitor H89 had no effect (data not shown).
Dysregulated STAT3 signaling by FGFR4 variants
interrupts growth hormone feedback
To determine whether differential STAT3 responses were
responsible for altered hormone gene expression, we compared the
hormonal responses of FGFR4-G388 and FGFR4-R388 cells to a
panel of growth factors. FGFR4-G388 cells with intact pY-STAT3
responses exhibited the expected GH inhibition in the presence of
IGF-1 and related growth factors and the expected PRL increase
in response to growth factors (Figure 4a). In contrast, and
consistent with their attenuated pY-STAT3 responses, FGFR4-
R388-expressing cells failed to suppress GH or mount a PRL
response (Figure 4a).
In complementary experiments we down-regulated STAT3 in
FGFR4-G388 cells. This forced STAT3 reduction resulted in
increased GH and reduced PRL (Figure S3). Conversely, forced
expression of STAT3 induced PRL and diminished GH
expression (Figure 4b, 4c). Moreover, introduction of the
dominant negative STAT3-Y705F diminished IGF-1 inhibition
of GH (Figure 4b, 4c). The STAT3-Y705F mutant also failed to
stimulate PRL expression further underscoring the requirement
for pY-STAT3 in mediating PRL induction. In contrast to the
impact of pY-STAT3, introduction of the constitutively active
serine STAT3-S727D or the serine inactive STAT3-S727A did
not alter GH or PRL responses (Figure 4b, 4c).
Taken together, these findings suggest that pY-STAT3, but not
pS-STAT3, plays a more important role in pituitary GH and PRL
regulation.
The FGFR4 polymorphism facilitates pituitary tumor
formation in vivo
To determine if the observed cellular actions of FGFR4
polymorphism translate into biologically relevant actions on
pituitary cell growth and function, we examined mice with
knock-in (KI) of the mouse homologue of the polymorphism,
Fgfr4-R385. Importantly, introduction of this SNP does not alter
Fgfr4 expression levels [28] and (Figure S1). Systematic examina-
tion of the pituitary glands from mice carrying the Fgfr4-R385
allele at different ages identified the presence of pituitary tumors
by 12 months of age. This revealed increased cellularity with loss
of the reticulin network representing the hallmark of true neoplasia
in this gland (Figure 5a–5d). Importantly, unlike the more
common prolactinomas which are seen sporadically in aging mice
[29], hormone staining identified GH (Figure 5e) but not PRL
(Figure 5f) production by these tumors. Further, we examined pS-
STAT3 in pituitary tissue from the knock-in mouse model. Fgfr4-
R385 KI mice displayed strong immunoreactivity for pS-STAT3
(Figure 5g) which was not noted in control Fgfr4-G385 mice
(Figure 5h). Double staining localized this pS-STAT3 in GH-
immunoreactive somatotrophs (Figure 5i) but not in other cell
types such as FSH-immunoreactive gonadotrophs (Figure 5j).
The frequency of these pituitary tumors and their morphologic
phenotypes according to Fgfr4 genotype are summarized in
Figure 5k. No GH-containing pituitary tumors were detected in
control littermates (Figure 5k).
To corroborate the pituitary phenotypic abnormalities we
compared circulating levels of the GH target growth factor IGF-
1. Shown in Figure 5l is the positive impact of the Fgfr4-R385
allele on circulating IGF-1 levels. In contrast, and consistent with
the in vitro data, mice carrying the Fgfr4-R385 allele did not
demonstrate high PRL levels, and instead showed a tendency to
lower concentrations compared to their Fgfr4-G385 littermates
(Figure 5m).
The FGFR4-R388 allele correlates with GH pituitary tumor
phenotype in humans
Given the ability of FGFR4-R388 to facilitate pituitary
tumorigenesis and GH production, we sought to identify evidence
linking these two processes in human disease. We first examined
STAT3 serine phosphorylation in human pituitary tissue. In the
normal gland, immunohistochemistry for pS-STAT3 revealed
strong reactivity in vascular endothelium (Figure 6a), providing an
internal positive control; adenohypophysial cells and stroma were
largely negative or showed only faint staining. All but one of 8
somatotroph adenomas exhibited strong positivity (Figure 6b)
whereas lactotroph adenomas (n=4) were negative or showed
focal weak positivity (Figure 6c). Four of 6 gonadotroph adenomas
and all but one of 7 null cell adenomas were also either negative or
weakly positive (Figure 6d).
We next compared GH levels and pituitary tumor size in 64
patients with pituitary tumors and acromegaly based on their
FGFR4 genotypic status. This examination identified a positive
correlation between circulating GH levels (r=0.622, p=0.006)
and pituitary tumor size in patients (n=30) harboring an FGFR4-
R388 allele. In contrast, patients homozygous for FGFR4-G388
(n=34) showed no relationship (r=0.23; p=0.468) between GH
levels and pituitary tumor size. Additionally, there was no
relationship between FGFR4 genotype and tumor size in non-
functional gonadotroph pituitary tumors (n=22) or lactotroph
adenomas (n=13). These data support a selective link between the
FGFR4-R388 allele, GH hormone production, and clinical
pituitary somatotroph tumor formation.
Discussion
The FGFR4-R388 SNP is known to promote breast cancer cell
motility and invasiveness [21]. It has also been associated with
accelerated cancer progression and treatment resistance [21–25].
However, the mechanisms underlying these actions remain
unclear. We show here that FGFR4-R388 significantly alters
Figure 1. The FGFR4-R388 polymorphism deregulates pituitary hormone production and cell growth. (a) FGFR4, prolactin (PRL), and
growth hormone (GH) protein expression were examined in pituitary GH4 mammosomatotroph cells stably expressing empty vector (control), the
prototypic receptor (FGFR4-G388), or the human polymorphic FGFR4-R388 variant. FGFR4-G388 enhances PRL production whereas FGFR4-R388
increases GH expression. (b) FGFR4 and PRL protein expression were examined in pituitary PRL235 lactotroph cells stably expressing empty vector
(control), the prototypic receptor (FGFR4-G388), or the human polymorphic FGFR4-R388 variant. FGFR4-G388 enhances PRL whereas FGFR4-R388
diminishes PRL expression. (c) GH4 cells or PRL235 cells expressing empty vector, FGFR4-G388, or FGFR4-R388 were plated in soft agar as described
under materials and methods. Shown is the change in the number of colonies (mean 6 SD obtained from four independent experiments).
Statistically significant (p,0.05) increased colony numbers were noted in cells expressing FGFR4-R388 as indicated.
doi:10.1371/journal.pgen.1002400.g001
FGFR4 Polymorphism in Pituitary Tumorigenesis
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receptor (FGFR4-G388), the polymorphic FGFR4-R388 variant
supports distinct signaling to deregulate pituitary growth hormone
production and cell growth in vitro and in vivo. In the mouse model
we report, Fgfr4 expression levels are not altered [28], providing
relevance to the human situation. Unlike the common sporadic
pituitary lactotroph adenomas in rodents or the intermediate lobe
corticomelanotroph pituitary tumors associated with several
mouse models of cancer [29], the Fgfr4 SNP knock-in mice
develop GH-producing pituitary tumors. The resulting GH/IGF-1
excess in these animals is potentially important in the enhanced
breast cancer progression associated with this model [28].
FGFR signaling relies heavily on recruitment of the immediate
substrate FRS2a through tyrosyl phosphorylation [30]. Using
hormone-producing pituitary cells we show that compared to
FGFR4-G388, FGFR4-R388 is associated with enhanced phos-
phorylation of FRS2a but not with the anticipated downstream
MAPK activation. Instead, FGFR4-R388 signaling is accompa-
nied by enhanced Src and STAT3 activation in pituitary cells.
Consistent with this feature, pharmacologic Src inhibition results
in greater growth inhibition by pituitary cells expressing FGFR4-
R388. Neither pharmacologic inhibition nor Src knockdown,
however, could alter the GH excess associated with FGFR4-R388.
Instead, the FGFR4 SNP variant relies heavily on serine (S727)
but not tyrosyl (Y705) phosphorylation of STAT3. These findings
suggested that while Src may play a role in promoting cell growth,
the observed hormone dysregulation was not intimately coupled
with this putative oncogene.
The current study implicates multiple consequences of altered
STAT3 modifications in the control of pituitary hormonal
balance. As anticipated, FGFR4-G388 supports FGF-induced
FRS2 phosphorylation to promote pY705-STAT3 activation. In
turn, pY705-STAT3 induces PRL, as has been shown previously
[31]. Conversely, the attenuated pY-STAT3 response, likely the
result of pS-STAT3 [32], associated with the FGFR4-R388 SNP
relieves GH from inhibition leading to higher expression of this
hormone. STAT3 is a well-recognized mediator of cytokine
signaling, and is known to regulate GH produced by the pituitary
gland [27]. Interestingly, STAT5 which is also implicated in GH
regulation [33] is not affected by this FGFR4 SNP in pituitary
cells.
Pituitary auto-feedback mechanisms are candidate pathways
whose interruption has become increasingly well-appreciated [2–
3]. PRL receptor knockout mice develop pituitary lactotroph
tumors [34]. Similarly, a somatic pituitary tumor-associated
mutation in the extracellular domain of the GH receptor (GHR)
disrupts N-terminal glycosylation of the receptor, thereby
impairing GHR trafficking to the membrane, limiting ligand
binding, and disrupting auto-feedback inhibition through dimin-
ished STAT activation [35–36]. Insulin and IGF-1 are growth
factors that are known to exert negative-feedback at the level of the
pituitary to inhibit GH [37]. In our study, insulin/IGF-1 efficiently
activated pY-STAT3 to inhibit GH expression. In contrast,
FGFR4-R388 failed to activate pY-STAT3 following ligand
stimulation. The importance of diminished pY-STAT3 in
mediating increased GH expression was further gleaned from
knockdown of this STAT. STAT3 down-regulation or introduc-
tion of dominant negative STAT3-Y705F resulted in augmented
GH production. Taken together, these data support the
importance of STAT3 in the feedback inhibition control of GH
regulation. In the bi-hormonal mammosomatotroph cell line
examined, this altered signaling had the reverse effect on PRL.
STAT3 down-regulation reduced PRL, whereas forced expression
of STAT3 increased PRL and reduced GH expression by
facilitating IGF-1 action. It is noteworthy that mice lacking pS-
STAT3 have reduced IGF-1 levels [38] providing a complemen-
tary model to the increased IGF-1 noted in our FGFR4-R385 KI
mice with pituitary somatotroph gain of pS-STAT3.
In contrast to the impact of FGFR4-G388 on pY-STAT3,
FGFR4-R388 was associated with serine STAT3 phosphorylation
(S727-STAT3). STAT3 is generally regarded as a requirement for
Src-mediated cell transformation as shown in many carcinomas
[39]. Traditionally, STAT3 oncogenic functions have been
regarded to rely on pY-STAT3 and its nuclear translocation.
However, more recently the positive impact of pS727-STAT3 on
cell transformation has emerged. Unlike the tyrosyl modification,
serine phosphorylated STAT3 has been also been described in the
mitochondria [40] and negatively modulates tyrosyl phosphoryla-
tion [32]. Mitochondrial pS-STAT3 as shown in this study has
been implicated in augmented electron transport complex and
ATP synthase activity to yield higher lactate dehydrogenase [27], a
critical metabolic requirement for transformed cells.
Previous studies have shown that pharmacologic inhibition of
wild-type FGFR4 was not effective in arresting pituitary tumor
xenografts [41]. Given our newly recognized FGFR4-R388 ability
to preferentially activate Src in pituitary cells, we set out to re-
examine the potential role of pharmacologic interruption on
pituitary tumor-associated parameters. Using the Src inhibitor
dasatinib [42], we demonstrate the ability of this agent to inhibit
colony formation by FGFR4-R388 pituitary tumor cells. Given the
recognized oncogenic actions of Src [43], and specifically in
pituitary tumorigenesis as shown here, our data provide new
insights into how this kinase might be an attractive therapeutic
target in patients harboring the FGFR4-R388 SNP. It is equally
plausible that inhibitors of STAT3 and those targeting oxidative
phosphorylation may be of potential value in modulating pituitary
tumors for therapeutic purposes.
In summary, we show that the heritable FGFR4-R388 allele
yields a receptor variant that signals in a distinct manner from its
prototypic FGFR4-G388 form in pituitary cells. Through its
Figure 2. FGFR4-R388 promotes Src and STAT3 signaling in pituitary tumor cells. (a) GH4 cells (left) and PRL235 cells (right) expressing
FGFR4-G388 or FGFR4-R388 were treated with the indicated panel of ligands under serum-free defined conditions. Equal amounts of cell lysates were
resolved by SDS-PAGE and analyzed by immunoblotting with the indicated antibodies. Results are representative of three independent experiments.
Compared to FGFR4-G388 cells which show ligand-dependent stimulation of FRS2a, FGFR4-R388 cells display enhanced FRS2a phosphorylation. Src
phosphorylation at Y416 is also appreciably higher in cells expressing FGFR4-R388 compared to those expressing FGFR4-G388 while Src
phosphorylation at Y527 is unchanged. While FGFR4-G388 supports ligand-induced tyrosyl phosphorylation of STAT3 at Y705, this effect is not shared
with FGFR4-R388, which instead results in sustained STAT3 phosphorylation at S727. (b) GH4 cells expressing FGFR4-R388 were treated with FGF1
under serum-free defined conditions in the presence or absence of the Src inhibitor dasatinib as detailed under Materials and Methods. Dasatinib
reduces Src phosphorylation and results in diminished pS-STAT3. Pituitary GH and PRL hormone levels, however, are unaffected by this Src inhibition.
(c) GH4 cells expressing FGFR4-G388 or FGFR4-R388 were grown in soft agar in the absence or presence of dasatinib. Shown are the colony numbers
expressed as the percent of control (mean 6 SD of measurements obtained from four independent experiments). Dasatinib significantly inhibit the
enhanced growth of cells expressing FGFR4-R388. (d) GH4 pituitary cells expressing FGFR4-R388 were transfected with siRNA targeting Src or a
scrambled control and examined by Western blotting. Densitometric values of knockdown relative to controls are shown immediately below.
doi:10.1371/journal.pgen.1002400.g002
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facilitates pituitary cell transformation. Further, the diminished
ability to respond through pY-STAT3 results in attenuated
negative feedback inhibition to augment pituitary GH expression.
Given the recognized impact of FGFR4-R388 [21–25] and of the
GH/IGF-I axis on cancer progression [44], the current findings
identify the common FGFR4 polymorphism as an endocrine
signal participating in these processes. It also highlights Src and
STAT3 as potential targets for the treatment of patients with
growth disorders in the context of the FGFR4 transmembrane
polymorphism.
Materials and Methods
Cell lines and cultures
As there are no human-derived hormone-producing pituitary
cell lines, we used rat pituitary GH4 mammosomatotroph cells
which were propagated in Ham F10 medium 12.5% horse and
2.5% fetal bovine serum (FBS; Sigma, Oakville, ON), 2 mM
glutamine, 100 IU/ml penicillin, and 100 mg/ml streptomycin
(37uC, 95% humidity, 5% CO2 atmosphere incubation). Rat
pituitary PRL235 lactotroph cells were propagated in DMEM
10% FBS, 2 mM glutamine, 100 IU/ml penicillin and 100 g/ml
streptomycin.
Plasmids and transfection
Plasmids encoding human prototypic FGFR4 (G388) or the
polymorphic form FGFR4-R388 were generated and stably
transfected into GH4 and PRL235 cells as previously described
[17]. Construct fidelity was confirmed by DNA sequencing after
introduction into pcDNA3.1. STAT3 expression vector was kindly
provided by M. Minden (University of Toronto), dominant
negative STAT3-Y705F, inactive STAT3-S727A, or constitutively
active STAT3-S727D were kindly provided by J. Chen (University
of Illinois) [42]. Cells were transfected using Lipofectamine 2000
(Life Technologies, Rockville, MD) according to the manufactur-
er’s instructions. Stable clones were selected using neomycin
(G418) at a concentration of 0.7 mg/ml. A minimum of 3 clones of
each isoform were pooled for further analyses in each of the cell
types examined.
siRNA knockdown
Oligonucleotides complementary to the gene of interest were
synthesized by Ambion and introduced by transfection using
lipofectamine 2000. Scrambled sequences of equal length were
used as controls.
Cell treatments
Ligand stimulations were performed on cells grown in 100 mm
plate (4610
6 cells/plate), pre-incubated as indicated for 1 hr or
24 hrs in serum-free defined medium (3 mg/ml putresine, 10-6 M
hydrocortisone, 10-11 M tri-iodothyronine T3, and 0.375%
albumin bovine factor V), without or with dasatinib (Sequoia
Research Products Ltd, Pangourne, UK, 100 nM), H-89 (Calbio-
chem, San Diego, CA, 1 mM), or G06983 (Sigma, 1 nM).
Treatments with IGF-1 (Sigma, 13 nM), insulin (Eli Lilly,
600 nM), FGF-1 (Sigma, 25 ng/ml) with heparin (10 U/ml),
and EGF (R & D systems, 25 ng/ml) were based on earlier dose
and time course studies ranging from 5 min up to 24 hrs.
Growth in soft agar
Twenty five hundred cells were plated in 35 mm dishes as a
single cell suspension in 0.3% agar in Ham F10 medium
supplemented with 15% horse serum and 10% CS over under-
layer of 0.5% agar prepared in Ham F10 as above. For Src
inhibition, cells were incubated with the pharmacologic inhibitor
dasatinib at concentrations ranging from 10
26 to 10
24 M. Colony
formation was monitored daily with a light microscope and
colonies photographed 4 weeks later as previously described [43].
Mitochondrial isolation and cytochrome c oxidase
activity
Cells were lysed by mechanical homogenization for mitochon-
drial extraction using Qproteome Mitochondria isolation kit
(Qiagen). Isolated fractions were analyzed by Western blotting to
detect the MnSOD mitochondrial marker. Effective exclusion of
contaminating cytoplasmic or nuclear proteins was confirmed by
detection of tubulin and acetylated histone 3 respectively.
Cytochrome C oxidase activity was used as a measure of electron
transport chain activity according to the manufacturer’s (Sigma)
instructions.
Western blotting and antibodies
Cells were lysed in lysis buffer (0.5% sodium deoxycholate,
0.1% sodium dodecyl sulfate, 1% Nonidet P-40 and 16 PBS)
containing proteinase inhibitors (100 mg/ml phenylmethylsulfonyl
fluoride (PMSF), 13.8 mg/ml aprotinin (Sigma), and 1 mM
sodium orthovanadate (Sigma). Total cell lysates were incubated
on ice for 30 mins, followed by micro-centrifugation at 10,000 g
for 10 min at 4uC. Protein concentrations of the supernatants were
determined by Bio-Rad method. Equal amounts of protein (50 mg)
were mixed with 56 SDS sample buffer, boiled for 5 mins and
separated by 8, 10, or 12% sodium dodecyl sulfate (SDS)-
polyacrylamide gel electrophoresis, and transferred onto PVDF
membranes (0.45 mm, Millipore, US). Intracellular and secreted
hormones were determined using the following antibodies:
polyclonal antisera to PRL or GH [donated by the National
Hormone and Pituitary Program (NHPP), National Institute of
Diabetes and Digestive and Human Development, Bethesdsa,
MD] applied at dilutions of 1:8,000 and 1:50,000, respectively.
Blots were incubated with polyclonal affinity–purified rabbit
antiserum against the carboxy terminus of FGFR4 (Santa Cruz,
Santa Cruz, CA). Immunoblotting was performed using anti-
FGFR4 (Santa Cruz, 1:1000), a monoclonal antibody to the V5-
tag (Invitrogen, Burlington, ON), anti-MnSOD (Millipore, Bill-
erica, USA), anti-FRS2a (R&D systems, Minneapolis, USA,
1:1000), anti-Erk1/2 (Sigma, 1:10000), anti-pFRS2a (Y196,
1:1000), anti-pErk1/2 (1:1000), anti-pY-STAT3 (Y705, 1:1000),
Figure 3. FGFR4-R388 relies on STAT3 serine phosphorylation to induce mitochondrial Cytochrome c activity and pituitary tumor
cell growth. GH4 pituitary cells stably expressing FGFR4-G388 (a–c, g–i), FGFR4-R388 (d–f, j–l), STAT3-S727A (m–o), or STAT3-S727D (p–r) were
labeled with MitoTracker RED CMX Ros to visualize mitochondria under serum-free defined conditions, fixed, and stained with anti-phospho-serine
STAT3 or anti-STAT3 followed by Alexa 488-conjugated secondary antibody. (b) Equal amounts of fractionated proteins from cells expressing FGFR4-
G388 or FGFR4-R388 were resolved by SDS-PAGE and immunoblotted for detection for pS-STAT3 and the following markers: Ac-Histone H3 (nuclear),
MnSOD (mitochondrial), or tubulin (cytoplasmic) as indicated. Results are representative of three separate experiments. (c) Cytochrome c oxidase was
measured as an index of mitochondrial metabolic activity. Shown are the mean values from 3 independent experiments. Statistically significant
differences are depicted as *p,0.05 or **p,0.01.
doi:10.1371/journal.pgen.1002400.g003
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PLoS Genetics | www.plosgenetics.org 8 December 2011 | Volume 7 | Issue 12 | e1002400Figure 4. FGFR4-G388, but not FGFR4-R388, signals through pY-STAT3 to regulate pituitary hormone gene expression. (a) Pooled
GH4 cells expressing FGFR4-G388 or FGFR4-R388 were treated with the indicated ligands for 24 hrs under serum-free defined conditions. Equal
amounts of cell lysates were resolved by SDS-PAGE and immunoblotting detection for PRL, GH, or actin as indicated. Results are representative of
three separate experiments. (b) GH4 cells expressing empty vector (control), wild-type (STAT3), dominant negative (STAT3-Y705F), constitutively
active STAT3-S727D, or inactive STAT3-S727A were treated with the indicated ligands for 24 hrs under serum-free defined conditions. Equal amounts
of cell lysates were resolved by SDS-PAGE and immunoblotting detection for PRL, GH, STAT3, or actin as indicated. (c) Densitometric ratios from three
separate experiments are shown immediately below.
doi:10.1371/journal.pgen.1002400.g004
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PLoS Genetics | www.plosgenetics.org 10 December 2011 | Volume 7 | Issue 12 | e1002400pS-STAT3 (S727, 1:1000), STAT3 (1:2500), anti-pSrc (Y416,
1:1000), Src (1:1000), anti-Tubulin (1:1000), anti-acetylated
Histone H3 (1:3000) were purchased from Cell Signaling
(Pickering, ON). Loading was monitored by detection of actin
(1:500, Sigma). Non-specific binding was blocked with 5% nonfat
milk in 16 TBST (Tris-buffered saline with 0.1% Tween-20).
After washing for 3610 mins in 16TBST, blots were exposed to
the secondary antibody (anti-mouse or rabbit IgG-HRP, Santa
Cruz) at a dilution of 1:2000 and were visualized using ECL
chemiluminescence detection system (Amersham, U.K.).
Figure 5. Mouse knock-in of the FGFR4 SNP facilitates pituitary GH cell tumorigenesis. (a) Thepituitaryglandsof Fgfr4-R385 knock-in mice
reveals multiple adenomas (arrows) (H&E stain; magnification610). (b) The Gordon Sweet silver stain confirms loss of acinar structures (magnification,
615). (c) The polygonal tumor cells form cords and nests (H&E stain; magnification 6150). (d) The reticulin stain shows the nodules exhibit total
breakdown of the reticulin fiber network, diagnostic of adenoma (Gordon Sweet silver stain; magnification,6150). (e) GH immunoreactivity is identified
in somaototroph cells andstronglyin adenomacells(Avidin-biotin-peroxidase complextechnique; magnification,6200).(f)Inthepituitaryoftheknock-
in mouse, PRL immunoreactivity is identified in mammosomatotroph cells but not in adenoma cells (Avidin-biotin-peroxidase complex technique;
magnification,6200). (g) Phospho-serine (pS727-STAT3) immunoreactivity is identified in pituitary cells of Fgfr4-R385
(+/+) mice but not (h) FGFR4-G385
(wild type) mice. (i) pS727-STAT3 immunoreactivity is co-localized in GH-expressing cells of Fgfr4-R385
(+/+) mice, but not (j) gonadotroph cells of the
same animals. (k) The frequency of pituitary tumor development in mice for Fgfr4-385 (G/G), heterozygote (G/R), or homozygote (R/R) is shown. (l)
Circulating IGF-1 levels as an integrated measure of pituitary GH output or prolactin (PRL) (m) were compared in mice of the corresponding FGFR4
genetic background. Shown are the mean 6SEM of 6 mice in each group where statistically significant differences (p,0.05) were noted.
doi:10.1371/journal.pgen.1002400.g005
Figure 6. STAT3 serine phosphorylation in human GH pituitary tumors. (a) Immunohistochemistry for phospho-serine (pS727-STAT3) in the
normal adenohypophysis reveals reactivity in vascular endothelium providing an internal positive control; there is focal faint staining in scattered
adenohypophysial cells and stroma is largely negative. (b) All but one of 8 somatotroph (GH) adenomas exhibited strong positivity whereas (c) all
lactotroph (PRL) adenomas (n=4) were negative or showed focal weak positivity. (d) Ten of 13 non-functional adenomas (6 gonadotrophs, 7 null cell)
were also either negative or weakly positive.
doi:10.1371/journal.pgen.1002400.g006
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Cells were grown in 2 chamber slides and pre-incubated in
serum-free define medium for 16 hrs. Cells were incubated with
MitoTracker Red CMXRos (Invitrogen) at 37uC for 20 minutes,
washed twice with PBS, fixed with 4% formaldehyde/PBS for
10 minutes, and washed three times with PBS. Cells were
permeabilized for 10 minutes in PBS with 0.2% Triton X-100
and blocked for 30 minutes with PBS containing 5% FBS. Cells
were first incubated with rabbit anti-STAT3 antibody (1:100) or
anti- pS-STAT3 antibody (1:100) for 30 minutes at room
temperature, washed three times with PBS, subsequently incubat-
ed with anti-rabbit IgG Alexa Fluor 488 for 30 minutes at room
temperature, and washed three times with PBS. Coverslips were
mounted in Fluoromount-G purchased from Electron Microscopy
Sciences (Hatfield, PA) on glass slides. Cells were examined with
Two-photon microscope (Zeiss LSM 510 META NLO), equipped
with a 636 water-immersion objective lens and filters optimized
for double-label experiments. Images were analyzed using the
LSM IMAGE browser.
Fgfr4-R385 knock-in mice
Fgfr4-R385 knock-in (KI) mouse were generated using standard
approaches as described previously [28]. Mice were maintained on
a pure C57BL/6 background. Genotyping was performed by PCR
of genomic tail-DNA [28]. The care of animals was approved by
the Institutional Animal Care facilities. Serum IGF-1 (Quantikine
ELISA kit) and Prolactin (Calbiotech) levels were measured
according to the manufacturer’s protocols. Tissues were frozen in
liquid nitrogen and stored at 270uC, or fixed in formalin and
embedded in paraffin for histologic and immunohistochemical
analyses. At least 6 animals were included at each time point for
experimental measures.
Immunocytochemistry
Pituitary glands were stained with the Gordon-Sweet silver
method to demonstrate the reticulin fiber network. Immunocyto-
chemical stains to localize adenohypophysial hormones were
performed as previously reported [17]. Primary polyclonal antisera
directed against rat pituitary hormones were used at the specific
dilutions: GH, 1:2500; prolactin, 1:2500; ß-thyroid-stimulating
hormone (ß-TSH), 1:3000; ß-follicle-stimulating hormone (ß-
FSH), 1:600; ß-luteinizing hormone (ß-LH), 1:2500 (National
Hormone and Pituitary Program, Rockville, MD); and adreno-
corticotropin pre-diluted preparation, which was further diluted
1:20 (Dako, Carpinteria, CA).
Human samples
Human pituitary tissues were retrieved from the files of the
University Health Network with REB approval. All had been fully
characterized according to currently accepted criteria [45]. Fasting
serum growth hormone levels were obtained from patients with
histologically proven GH-producing pituitary adenomas. Pituitary
tumor size was based on the maximal diameter noted on magnetic
resonance imaging (MRI). FGFR4 germline genotyping was
performed on DNA isolated from circulating while blood cells as
described [21].
Ethics statement
The care of animals was approved by the Institutional Animal
Care facilities. Human pituitary tumors were retrieved from the
files of the University Health Network with REB approval.
Statistical analysis
Data are presented as mean 6 standard deviation (SD). In the
experimental models, differences were assessed by the unpaired,
two-sided t test. P,0.05 was considered statistically significant.
The analysis of surgical human tumor specimens applied Fisher’s
exact test.
Supporting Information
Figure S1 Endogenous Fgfr4 expression in pituitary cell lines
and primary pituitaries of Fgfr4-R385 knock-in mice. Fgfr4
protein expression was examined by western blotting in the
indicated GH4 and PRL235 cell lines and in primary pituitaries of
Fgfr4-R385 knock-in mice. Native HEK239 cells show minimal
FGFR4 reactivity.
(TIF)
Figure S2 STAT3 serine phosphorylation induces pituitary
tumor cell growth. GH4 cells expressing wild-type (STAT3-WT),
inactive (STAT3-Y705F), constitutively active (STAT3-S727D), or
inactive (STAT3-S727A) STAT3 were grown in soft agar. Shown
are percentages compared to vector controls and expressed as a
mean 6 SD of measurements obtained from four independent
experiments. Statistically significant differences are depicted as
*p,0.05 or **p,0.01.
(TIF)
Figure S3 STAT3 down-regulation alters the Growth hor-
mone/Prolactin balance in GH4 cells. GH4 cells expressing
FGFR4-G388 were transfected with siRNA oligonucleotides
directed at STAT3. This forced STAT3 reduction results in
increased GH and reduced PRL as shown by western blotting with
corresponding densitometric values immediately below.
(TIF)
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